As of March 31, 2024, the company had 63 active clients as compared to 62 in FY23.
Manish Gupta, Chairman and Chief Executive Officer, said, “We are pleased with our continued performance this quarter and the full year. Today in the marketplace we are known as a digital first commercialisation partner to the global life sciences industry.
“We have 63 active clients and work with all the top 20 global pharmaceutical companies. Our revenues very closely mirrors the global life sciences industry’s spends on operations. 69% of our revenues come from the top 20 Pharma companies. Global Life Sciences industry is more than $1.8 trillion Industry. We are excited about the opportunity in front of us,” Gupta says.
As of March 31, 2024, Indegene had an employees count of 5,081, while voluntary attrition was 15.7%.
Earlier this month, the company raised ₹1,842 crore via IPO, which received an overwhelming response from investors, with the issue subscribing 70.3 times. The IPO comprises a fresh issue of equity shares worth up to ₹760 crore and an offer for sale (OFS) of shares worth ₹1,082 crore by existing shareholders and investors.
The company intends to use capital raised from the issuance of fresh equities to fund the repayment of debts of one of its material subsidiaries, ILSL Holdings, Inc. A part of the capital will be used for funding the capital expenditure requirements of the company and one of its subsidiaries, Indegene, Inc., as well as to meet general corporate purposes and inorganic growth.
Established in 1998, the company helps life sciences industry with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales/marketing support.
(DISCLAIMER: The views and opinions expressed by investment experts on fortuneindia.com are either their own or of their organisations, but not necessarily that of fortuneindia.com and its editorial team. Readers are advised to consult certified experts before taking investment decisions.)